Who we are
The King’s College London Gene Therapy Vector Facility (GTVF) provides comprehensive GMP-grade viral vector manufacturing services. This includes Lentiviral Vector (LV), Retroviral Vector (RV) and Adeno-Associated Viral Vector (AAV) production for early-phase clinical trials, alongside substantial programmes in process innovation, knowledge transfer and training to address critical skills shortages.
In partnership with the Network of Innovation Hubs, our vision is to ensure that the UK capitalises on its outstanding academic medical research to deliver novel gene therapies to patients, providing transformative treatments for currently intractable conditions, and generating a vibrant economic landscape.
The GTVF is run by a large, industry-leading team of ~60 people who have extensive experience in delivering end-to-end viral vector manufacture for both academic and commercial clients, with a focus on early-stage clinical trials.
Your partner for comprehensive vector manufacture
The GTVF at a glance:
- GMP viral vector manufacturing
- Lentiviral vector
- Retroviral vector
- Adeno-associated viral vector
- Drug substance and drug product manufacturing
- Established LV, RV and AAV platform processes
- Packaging plasmids available for use
- >120 GMP viral vector batches delivered over 20-year legacy
- 4 active, MHRA accredited, GMP production cleanrooms
- ~60 dedicated staff
- Commercial and academic project support
- Focus on early-stage clinical trials, vector provided to UK, Europe, USA
- Competitive pricing to enable access to GMP vector without the commercial price-tag
- Comprehensive project support including regulatory
Get In Touch
Contact us to discuss your lentiviral vector, retroviral vector, and adeno-associated viral vector GMP manufacturing needs: